Last reviewed · How we verify
Acute intermittent porphyria
Approved treatments
- Thorazine · Generic (originally Rhône-Poulenc/Sanofi)
- Panhematin · Rush University Medical Center
- Normosang
Normosang replenishes heme, a crucial component in hemoglobin production, to treat Acute Intermittent Porphyria.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Acute intermittent porphyria patent landscape — cliff calendar, originator estates, attackable patents
- Acute intermittent porphyria treatment landscape brief
- Acute intermittent porphyria treatment updates RSS
Frequently asked questions about Acute intermittent porphyria
What drugs treat Acute intermittent porphyria?
Tracked treatments include Thorazine, Panhematin, Normosang.
What is the treatment for Acute intermittent porphyria?
Standard treatment for Acute intermittent porphyria includes Thorazine, Panhematin, Normosang. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Acute intermittent porphyria patent cliff · Acute intermittent porphyria CI report
- Treatment: Thorazine · Generic (originally Rhône-Poulenc/Sanofi)
- Treatment: Panhematin · Rush University Medical Center
- Treatment: Normosang
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing